ArticleFrontiers in oncology2025
Risk factors for adverse reactions caused by abemaciclib in breast cancer therapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In recent years, a range of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have been identified as significantly improving the survival of patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). As the use of CDK4/6 inhibitors continues to increase, safety concerns have garnered increasing attention. Herein, this study analyzed adverse reactions in breast cancer patients receiving a CDK4/6 inhibitor abemaciclib, with a focus on identifying risk factors for diarrhea and neutropenia through regression analysis. Methods: In this study, a total of 216 BC patients receiving abemaciclib were enrolled. Follow-up observations towards the baseline and clinical characteristics in these patients were exhibited. The evaluation of adverse effects (AEs) in these patients was performed based on the clinical practice of abemaciclib whole-course management and the consensus on the management. Subsequently, we focused on the two most common adverse reactions during the use of abemaciclib, namely diarrhea and neutropenia. Furthermore, analysis of factors influencing incidence of diarrhea and neutropenia was executed using the univariate analysis and multivariate logistic regression analysis. Results: The safety profile of abemaciclib was manageable, and the drug was well tolerated by patients. The incidence of AEs was greater in the gastrointestinal system, blood and lymphatic system, liver system, renal system, muscular and skeletal systems, and skin and subcutaneous tissue systems. Age stratification and gastrointestinal diseases were independent risk factors for grade 2-3 diarrhea. Alternatively, the Eastern Cooperative Oncology Group (ECOG) score was a factor associated with the risk for grade 3-4 neutropenia. Baseline BMI classification, baseline white blood cell (WBC) count and baseline albumin (ALB) stratification were factors associated with protection against grade 3-4 neutropenia. Discussion: This study retrospectively collected, processed, analyzed, and evaluated the safety profile of abemaciclib. Additionally, potential influencing factors associated with common adverse reactions including diarrhea and neutropenia were explored to provide a foundation for its rational clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.